Skip to content

Clinician Satisfaction With the VERABAND™

A Study of Clinician Satisfaction and Likelihood of Clinical Adoption of the VERABAND™

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06080464
Enrollment
360
Registered
2023-10-12
Start date
2025-06-09
Completion date
2027-06-01
Last updated
2026-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Low-back Pain

Brief summary

The VERABAND™ is a newly-developed, disposable, wearable activity monitor. The researchers will assess clinician satisfaction with the usability and likelihood of clinical adoption of the newly-developed, disposable, wearable activity monitor, across multiple clinical sites in the chronic low back pain (cLBP) population.

Detailed description

A total of 340 cLBP patients (estimating n=300 completers) will be recruited and evaluated under an approved institutional review board (IRB) protocol by a total of 20 clinician participants distributed across multiple tertiary pain clinics. Consented patient participants will be given a VERABAND™ activity monitor during an initial clinic visit (baseline) and will then be tracked longitudinally after beginning a new pain treatment regime as part of their normal ongoing care. VERABAND™ activity data reports (including a summary broken down by week) will subsequently be provided to treating clinicians prior to each patient's follow-up clinic visit. The primary outcome will be clinician satisfaction with usability of the VERABAND™ system to support clinical cLBP management, regardless of the specific treatment(s) implemented or their analgesic effectiveness. Each clinician will complete a usability satisfaction survey at the end of each patient's episode of care, which allows for exploratory analyses to identify whether the VERABAND™ system is perceived to be more useful for specific patient phenotypes (e.g., those with higher levels of pain and/or disability or specific psychological characteristics).

Interventions

OTHERVERABAND information

The device, VERABAND™, activity data reports (including a summary broken down by week) will be provided to treating clinicians prior to each patient's follow-up clinic visit.

Sponsors

University of Michigan
Lead SponsorOTHER
National Institute of Neurological Disorders and Stroke (NINDS)
CollaboratorNIH
Arbor Medical Innovations, LLC
CollaboratorUNKNOWN

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

Any treating clinician at a recruiting tertiary pain clinic will be eligible to participate. Patient participants must meet the following criteria: Inclusion Criteria: * Ambulatory * Diagnosis of chronic low back pain (cLBP) according to the criteria of National Institute of Health (NIH) Task Force on Research Standards for cLBP * Answering 'Yes' to the question: Does your low back pain interfere with your mobility? * Starting any new non-surgical treatment or combination of treatments for cLBP as part of their normal ongoing care, including medications; physical therapy/exercise; integrated therapies (e.g., massage, acupuncture, yoga); cognitive- behavioral therapy; and/or interventional procedures (e.g., epidural steroid or facet joint injections) * Willingness to wear a VERABAND™ continuously until their next clinic visit and return used devices in the mail.

Exclusion criteria

* Clinical findings suggesting the presence of ongoing systemic disease, including fever, weight loss, initiation of pain following major trauma, immunosuppression, intravenous drug use, recent bacterial infection, severe or persistent sensory or motor involvement of bowel, bladder, or lower extremity; or any condition that would greatly limit physical activity not due to pain. * Inability to speak and write English. * Visual or hearing difficulties that would preclude participation. * Severe psychiatric disorders that in the opinion of the investigative team would interfere with participation in the study. This includes any active suicidal ideations or history of suicide attempts. Exclusions will be based on self-reported medical history or chart review and in accordance with Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria. * Individuals receiving disability or compensation or involved in litigation. * Scheduled surgery before follow-up.

Design outcomes

Primary

MeasureTime frameDescription
Measure clinician satisfaction of the usability of the VERABAND™ using the System Usability Scale (SUS)approximately 7 weeksThe SUS is comprised of 10 statements: Each statement is accompanied by a five-point scale Likert response option. The SUS ranges from 10-50 and the higher scores indicate higher clinician satisfaction with usability.
Measure the likelihood of clinical adoption of the VERABAND™ using Item 1 of the System Usability Scale (SUS)approximately 7 weeksThe SUS item is a five-point scale Likert response ranging from 1-5. Higher scores indicate increase likelihood of clinical adoption of the VERABAND™

Countries

United States

Contacts

CONTACTKristi Pickup, MSW
knpicku@med.umich.edu734-764-4072
PRINCIPAL_INVESTIGATORDaniel Whibley, PhD

University of Michigan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 4, 2026